JP2004502460A5 - - Google Patents

Download PDF

Info

Publication number
JP2004502460A5
JP2004502460A5 JP2002509500A JP2002509500A JP2004502460A5 JP 2004502460 A5 JP2004502460 A5 JP 2004502460A5 JP 2002509500 A JP2002509500 A JP 2002509500A JP 2002509500 A JP2002509500 A JP 2002509500A JP 2004502460 A5 JP2004502460 A5 JP 2004502460A5
Authority
JP
Japan
Prior art keywords
domain
nucleic acid
protective
immune response
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002509500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004502460A (ja
Filing date
Publication date
Priority claimed from GBGB0016702.3A external-priority patent/GB0016702D0/en
Application filed filed Critical
Publication of JP2004502460A publication Critical patent/JP2004502460A/ja
Publication of JP2004502460A5 publication Critical patent/JP2004502460A5/ja
Pending legal-status Critical Current

Links

JP2002509500A 2000-07-08 2001-07-06 発現系 Pending JP2004502460A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016702.3A GB0016702D0 (en) 2000-07-08 2000-07-08 Expression system
PCT/GB2001/003065 WO2002004646A1 (en) 2000-07-08 2001-07-06 Expression system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011180293A Division JP2012010706A (ja) 2000-07-08 2011-08-22 発現系

Publications (2)

Publication Number Publication Date
JP2004502460A JP2004502460A (ja) 2004-01-29
JP2004502460A5 true JP2004502460A5 (https=) 2008-08-21

Family

ID=9895205

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002509500A Pending JP2004502460A (ja) 2000-07-08 2001-07-06 発現系
JP2011180293A Pending JP2012010706A (ja) 2000-07-08 2011-08-22 発現系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011180293A Pending JP2012010706A (ja) 2000-07-08 2011-08-22 発現系

Country Status (10)

Country Link
US (3) US7537771B2 (https=)
EP (2) EP1301606A1 (https=)
JP (2) JP2004502460A (https=)
CN (2) CN101012458A (https=)
AU (1) AU2007201553B8 (https=)
CA (2) CA2413045C (https=)
GB (1) GB0016702D0 (https=)
RU (2) RU2270865C2 (https=)
WO (1) WO2002004646A1 (https=)
ZA (1) ZA200210206B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
EP1575505A4 (en) * 2002-09-10 2007-01-24 Vical Inc CODON OPTIMIZATION-BASED POLYNUCLEOTIDE VACCINES AGAINST BACILLUS ANTHRACIS INFECTION
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1572977B1 (en) 2002-11-15 2010-03-03 Gen-Probe Incorporated Assay and compositions for detection of bacillus anthracis nucleic acid
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
FR2860005A1 (fr) * 2003-09-23 2005-03-25 Univ Aix Marseille Ii Methode de detection d'agents bacteriens ou viraux de bioterrorisme
WO2005030991A1 (fr) * 2003-09-23 2005-04-07 Universite De La Mediterranee (Aix-Marseille Ii) Methode de detection d’agents bacteriens ou viraux de bioterrorisme
GB0401036D0 (en) * 2004-01-17 2004-02-18 Royal Holloway University Of L Improvements in or relating to vaccination
US8101735B2 (en) 2004-06-16 2012-01-24 Health Protection Agency Preparation of protective antigen
US7355027B2 (en) * 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
CN100336908C (zh) * 2004-09-10 2007-09-12 中国人民解放军军事医学科学院微生物流行病研究所 一种制备重组炭疽保护性抗原的方法及其专用表达质粒
WO2006068647A1 (en) * 2004-12-20 2006-06-29 United States Army Medical Research And Materiel Command Internal positive control for probe-based nucleic acid molecule assays and methods of making and using thereof
GB0504940D0 (en) * 2005-03-10 2005-04-20 Secr Defence Vaccine formulation
EP1954307A4 (en) 2005-11-14 2009-12-02 Univ Maryland Biotech Inst ORAL VACCINES AGAINST MILZBRAND ON SALMONELLA BASE
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
GB0607462D0 (en) 2006-04-13 2006-05-24 Avecia Ltd Assay
JP2008231063A (ja) * 2007-03-22 2008-10-02 Takano Foods Kk 納豆菌ワクチン
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
US20100183675A1 (en) * 2009-01-22 2010-07-22 Allan Watkinson Stable vaccine compositions and methods of use
US8187611B2 (en) * 2009-10-29 2012-05-29 Albert Einstein College Of Medicine Of Yeshiva University Anti-peptide antibodies that cross react with protective antigen of Bacillus anthracis and uses thereof
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen
CN101798565B (zh) * 2010-02-26 2013-08-07 中国人民解放军军事医学科学院生物工程研究所 能在芽孢表面展示pa20蛋白的炭疽芽孢杆菌及其应用
RU2633508C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633504C1 (ru) * 2016-12-27 2017-10-12 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН) Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2115433C1 (ru) * 1992-08-28 1998-07-20 Научно-исследовательский институт микробиологии МО РФ Вакцина сибиреязвенная комбинированная
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
RU2110575C1 (ru) * 1995-07-19 1998-05-10 Государственное Федеральное предприятие Государственный научный центр прикладной микробиологии Рекомбинантная плазмидная днк pro pf 5, определяющая синтез капсульного антигена fi возбудителя чумы и протективного антигена возбудителя сибирской язвы, и способ конструирования рекомбинантной плазмидной днк pro pf5
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system

Similar Documents

Publication Publication Date Title
JP2004502460A5 (https=)
RU2003103779A (ru) Экспрессионная система
ATE292685T1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
RU2004134341A (ru) Экспрессирующая система
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
ATE471335T1 (de) Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
JP2002537791A5 (https=)
JP2017536835A5 (https=)
JP2002542827A5 (https=)
JP2018537087A5 (https=)
JP6958818B2 (ja) ヒトパピローマウイルスタイプ５８のｌ１タンパク質の突然変異
JP2003510050A5 (https=)
WO2006039045A3 (en) Adenoviral vectors able to transduce apcs, potential use in immune response generation
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
CA2572555A1 (en) Fusion protein of porcine reproductive and respiratory syndrome virus as prrs vaccine
CA2135201A1 (en) Universal coronavirus vaccine
CA2385325A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP2003530872A5 (https=)
Hsu et al. Characterization of polymorphism displayed by the coat protein mutants of tomato bushy stunt virus
JP2020509770A5 (https=)
JP2004502446A5 (https=)
BR112020024694A2 (pt) Mutante de proteína l1 do tipo 39 de papilomavírus humano
Klein et al. Haloarchaeal myovirus φCh1 harbours a phase variation system for the production of protein variants with distinct cell surface adhesion specificities
AU704594B2 (en) Production of recombinant peptides as natural hydrophobic peptide analogues
JP2005512518A5 (https=)